SVB Leerink Maintains Outperform on 4D Molecular Therapeutics, Lowers Price Target to $28
SVB Leerink analyst Mani Foroohar maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and lowers the price target from $30 to $28.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
4D Molecular Shares Updated Data From Fabry Disease Trial
4D Molecular Therapeutics Inc (NASDAQ: FDMT) has posted updated interim data from the Phase 1/2 trial of 4D-310 in Fabry disease at the
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours:
4D Molecular Therapeutics Announces Updated Interim Results From 4D-310 Phase 1/2 Clinical Trial In Patients With Fabry Disease At 18th Annual WORLDSymposium
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced updated interim clinical data from the ongoing Phase